Adimab LLC. Announces New Antibody Discovery Program with Gilead Sciences, Inc. (GILD) and Initiates First Bispecific Antibody Collaboration
4/19/2012 10:05:20 AM
LEBANON, N.H.--(BUSINESS WIRE)--Adimab, LLC, a technology leader in the discovery of fully human therapeutic antibodies, today announced the initiation of two new independent research collaborations. Adimab and Gilead Sciences, Inc. (Nasdaq:GILD) of Foster City, CA, have initiated a research collaboration to identify therapeutic antibodies against two targets selected by Gilead. In addition, Adimab has expanded one of its current partnerships to initiate a new project in the area of bispecific antibodies. Adimab today announced the achievement of several technical milestones from its ongoing collaborations with Novartis, Merck, Merrimack, and Genentech.
comments powered by